Jaguar Health, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report; the filing does not provide a standalone fourth-quarter income statement. Financial comparisons below are year-over-year. Amounts are in U.S. dollars.
Business context
Jaguar is a commercial-stage pharmaceutical company focused on gastrointestinal disorders. Its lead product, Mytesi (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy. The company is developing additional human indications and lechlemer, a second-generation candidate, while animal-health activity is more limited.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Revenue | $9.385 million | $5.775 million | Up 62.5%; primarily attributed to Mytesi’s April 2020 list-price adjustment. |
| Cost of product revenue | $3.280 million | $3.816 million | Down 14.0%. |
| Gross profit / gross margin | $6.105 million / approximately 65% | $1.959 million / approximately 34% | Calculated from reported revenue and cost of product revenue. |
| Operating expenses | $36.032 million | $34.723 million | Includes $1.647 million Series B inducement expense and $3.696 million Series 3 warrant inducement expense in 2020. |
| Operating loss | $26.647 million | $28.948 million | Improved year over year. |
| Net loss | $33.809 million | $38.539 million | Improved year over year; 2020 included a $2.696 million loss from changes in fair value of financial instruments. |
| Net loss attributable to common shareholders | $38.648 million | $44.726 million | Includes preferred-stock and warrant-related deemed dividends. |
| Operating cash flow | $(15.278) million | $(20.457) million | Cash used in operations remained substantial. |
| Cash at year-end | $8.090 million | $3.495 million | 2020 financing cash inflow was $19.492 million. |
| Current assets / current liabilities | $17.792 million / $13.220 million | $9.522 million / $15.392 million | Year-end 2020 working capital was approximately $4.572 million. |
| Notes payable, net of discounts | $16.210 million | $7.228 million | Includes current and non-current amounts; reported face amount before discounts was $33.892 million. |
| Stockholders’ equity / accumulated deficit | $17.202 million / $(166.899) million | $10.673 million / $(133.090) million | The company continued to have a large accumulated deficit. |
Mytesi generated $9.309 million of 2020 revenue; animal-health revenue was $76,000. One customer represented 97% of total net revenue and 95% of year-end accounts receivable. The filing identifies the Mytesi distributor/customer concentration as a material exposure.
After year-end, the company reported $33.8 million of cash as of the financial-statement issuance date, following a January 2021 public offering and other financing. Management believed available cash would fund obligations for at least 12 months after issuance. This later cash figure is not the December 31, 2020 balance.
Material changes versus 2019
- Revenue rose, but management attributed most of the increase to the Mytesi list-price adjustment rather than describing it as volume-led growth. Gross Mytesi sales increased from $8.249 million to $20.434 million, while rebates, discounts, returns, and wholesaler fees reduced 2020 net sales to $9.309 million.
- Research and development expense increased 10.2% to $6.413 million, including higher consulting, formulation, and regulatory costs for pipeline work. Sales and marketing expense decreased 4.7% to $6.609 million, reflecting lower personnel costs partly offset by increased direct marketing.
- General and administrative expense increased 6.6% to $14.387 million. It included a $1.0 million Atlas trial-delay charge, and legal and public-company costs also increased.
- Cash used in operations declined to $15.278 million from $20.457 million, while financing remained important to funding operations. Year-end notes payable, net, increased to $16.210 million.
- Several preferred-stock and warrant transactions, debt exchanges, and equity issuances materially affected reported expenses, common-shareholder losses, and share counts.
Outlook, management commentary, and risks
- Mytesi development: A pivotal Phase 3 trial for prophylaxis of cancer therapy-related diarrhea began in October 2020 and was enrolling. Top-line results from the investigator-sponsored HALT-D study were expected in the second half of 2021. These are expectations, not reported results.
- Other pipeline: The filing anticipated a Phase 1/2 pediatric study for congenital diarrheal disorders and top-line results from a functional-diarrhea study in the fourth quarter of 2021. Lechlemer remained pre-IND, with NIAID-supported toxicology work underway; development plans and milestones were funding-dependent.
- Animal health: Jaguar expected Canalevia could be available under conditional approval for chemotherapy- and exercise-induced diarrhea in dogs in the second half of 2021. Approval and timing were not assured.
- COVID-19 and Europe: The company was exploring crofelemer for COVID-related diarrhea and a European conditional-authorization pathway. The FDA had denied its emergency-use authorization request in April 2020. A February 2021 MOU gave a proposed Dragon SPAC exclusivity to negotiate a potential transaction involving Napo EU; it was not a completed merger or definitive license.
- Funding and obligations: Management expected continued losses and negative operating cash flows and stated that additional capital might be needed. Royalty-interest financings created minimum payment obligations; the filing’s risk summary lists minimum royalty payments of $2.3 million in 2021, $6.7 million in 2022, $18.0 million in 2023, and $11.3 million in 2024. The company also had secured borrowings and significant future contractual commitments.
- Accounting controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2020, citing material weaknesses in the financial-statement close and review process, staffing, and review of fair-value assumptions and contractual covenants. The auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness.
- Other notable items: Jaguar settled the Atlas trial-delay obligation with shares and pre-funded warrants after deciding not to initiate the contracted NP-500 Phase 2 study; the filing reports a $1.0 million loss. A proposed $2.6 million class-action settlement relating to the 2017 merger was subject to final court approval, with the company expecting D&O insurance to fund the consideration. The filing also identifies supply-chain dependence, COVID-19 disruption, competition, reimbursement, dilution, Nasdaq listing, and stock-price volatility as risks.
Important facts for investors to verify
- Whether Mytesi revenue growth persists through increased demand and access, rather than price changes, and how rebates, discounts, returns, and wholesaler fees affect net sales.
- Whether the company can reduce customer concentration and maintain distribution, reimbursement, and patient access for Mytesi.
- Actual cash runway, subsequent financing proceeds, debt terms, royalty-payment schedules, and the effect of minimum payments on liquidity.
- Clinical-trial enrollment, results, regulatory milestones, and funding for CTD, pediatric indications, lechlemer, and Canalevia; distinguish completed milestones from management expectations.
- Progress in remediating material weaknesses and whether future filings report effective controls.
- Share-count changes, warrant and option overhang, and further dilution from equity financing or debt exchanges.
- Final disposition of the proposed merger-related settlement and status of the Dragon SPAC/Napo EU proposal.